SCHEMBL1594868

SCHEMBL1594868

OCCOCCOCCOCCOCCOc1ccc(OCCOCCOCCOCCOCCOCc2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
RECQL P46063 1/20 0.55
APP P05067 7/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 2/20 0.51
MEN1 O00255 1/20 0.51
USP2 O75604 1/20 0.51
CYP3A4 P08684 1/20 0.51
MAPK1 P28482 1/20 0.51
CASP1 P29466 1/20 0.51
KMT2A Q03164 1/20 0.51
SLCO1B3 Q9NPD5 1/20 0.51
SLCO1B1 Q9Y6L6 1/20 0.51
LTA4H P09960 1/20 0.50
EPHX2 P34913 1/20 0.50
CYP1A2 P05177 1/20 0.50
PTGS1 P23219 1/20 0.50
SLC6A2 P23975 1/20 0.50
CYP2C19 P33261 1/20 0.50
PTGS2 P35354 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29066838 0.97 ALDH1A1 (0.60) ALDH1A1RECQLAPPSMN1; SMN2LMNA
SCHEMBL18429764 0.93 LMNA (0.59) ALDH1A1RECQLAPPSMN1; SMN2LMNA
SCHEMBL29045776 0.93 LMNA (0.59) ALDH1A1RECQLAPPSMN1; SMN2LMNA
SCHEMBL1594368 0.92 ALDH1A1 (0.48) ALDH1A1RECQLAPPSMN1; SMN2LMNA
SCHEMBL16594362 0.91 TSHR (0.56) APPSMN1; SMN2LMNAMAPK1LTA4H
SCHEMBL16437099 0.89 TSHR (0.58) ALDH1A1RECQLSMN1; SMN2LMNAMEN1
SCHEMBL607698 0.89 TSHR (0.58) ALDH1A1RECQLSMN1; SMN2LMNAMEN1
SCHEMBL24748 0.89 TSHR (0.58) ALDH1A1RECQLSMN1; SMN2LMNAMEN1
SCHEMBL606328 0.89 TSHR (0.58) ALDH1A1RECQLSMN1; SMN2LMNAMEN1
SCHEMBL12865302 0.89 TSHR (0.58) ALDH1A1RECQLSMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7919653-B2 Method of inhibiting nonspecific interaction between molecules on solid phase support REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) 2011-04-05 US disclosed
US-7919653-B2 Method of inhibiting nonspecific interaction between molecules on solid phase support REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) 2011-04-05 US disclosed
EP-2157429-A2 Method of inhibiting nonspecific interaction between molecules on solid phase support Reverse Proteomics Research Institute Co., Ltd (JP) 2010-02-24 EP disclosed
US-20060177943-A1 Method of inhibiting nonspecific interaction between molecules on solid phase support REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) 2006-08-10 US disclosed
EP-1553412-A1 METHOD OF INHIBITING NONSPECIFIC INTERACTION BETWEEN MOLECULES ON SOLID PHASE SUPPORT Reverse Proteomics Research Institute Co., Ltd (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060177943-A1 Method of inhibiting nonspecific interaction between molecules on solid phase support CD2BP2, CD14, SPR ALDH1A1 4627/4885RECQL 1674/4885APP 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.